Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 107 Cr.
- Current Price ₹ 133
- High / Low ₹ 148 / 128
- Stock P/E 17.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 34.2 %
- ROE 55.3 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 86.3 to 55.9 days.
Cons
- Promoter holding has decreased over last quarter: -24.6%
- Company might be capitalizing the interest cost
- Working capital days have increased from 38.4 days to 99.6 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 23.70 | 35.21 | 35.13 | 49.13 | |
| 20.12 | 31.95 | 26.74 | 39.59 | |
| Operating Profit | 3.58 | 3.26 | 8.39 | 9.54 |
| OPM % | 15.11% | 9.26% | 23.88% | 19.42% |
| 0.02 | 0.34 | 0.31 | 0.51 | |
| Interest | 1.62 | 1.33 | 0.85 | 1.11 |
| Depreciation | 0.75 | 0.73 | 0.68 | 0.67 |
| Profit before tax | 1.23 | 1.54 | 7.17 | 8.27 |
| Tax % | 59.35% | 20.13% | 32.22% | 26.24% |
| 0.49 | 1.23 | 4.87 | 6.11 | |
| EPS in Rs | 9.80 | 24.60 | 97.40 | 10.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 28% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 132% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 55% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 5.93 |
| Reserves | -1.40 | -0.18 | 5.37 | 10.29 |
| 17.62 | 16.19 | 17.09 | 15.61 | |
| 10.68 | 13.16 | 10.91 | 10.70 | |
| Total Liabilities | 27.40 | 29.67 | 33.87 | 42.53 |
| 12.33 | 12.20 | 11.59 | 10.99 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.02 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 |
| 15.06 | 17.46 | 22.27 | 31.51 | |
| Total Assets | 27.40 | 29.67 | 33.87 | 42.53 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 4.95 | 3.35 | 0.28 | -1.76 | |
| -0.37 | -0.55 | -0.06 | -0.02 | |
| -4.58 | -2.76 | 0.05 | 1.67 | |
| Net Cash Flow | -0.01 | 0.04 | 0.27 | -0.11 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 96.10 | 98.17 | 104.94 | 55.87 |
| Inventory Days | 208.46 | 114.92 | 273.22 | 347.26 |
| Days Payable | 359.58 | 262.67 | 210.40 | 112.29 |
| Cash Conversion Cycle | -55.01 | -49.58 | 167.75 | 290.83 |
| Working Capital Days | -16.02 | -20.84 | 36.26 | 99.63 |
| ROCE % | 17.21% | 40.64% | 34.24% |
Documents
Annual reports
No data available.
Business Profile[1]
Curis Lifesciences is a pharmaceutical company engaged in the production of a wide range of formulations across tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments.